cnl_21

Epac - Associazione Onlus

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Malattie autoimmuni

Fai una donazione

Sostieni EpaC Onlus

Newsletter EpaC

Aggiornati via email. Iscriviti

Notiziario Epac

Periodico cartaceo. Iscriviti

Sangue Infetto

Visita il sito - legge 210/92

News nuovi farmaci in Inglese

First ever successful use of Daclatasvir and GS-7977 (Sofosbuvir) , an IFN-free regimen, in a Liver Transplant recipient with severe recurrent Hepatitis C

14/01/2013

Telaprevir French Cohort Authorization for Temporary Use in Genotype 1 Hepatitis C Cirrhotic Patients with Prior Partial Response or Relapse

13/12/2012

GILEAD ANNOUNCES SUSTAINED VIROLOGIC RESPONSE RATE OF 78% FROM PHASE 3 STUDY OF SOFOSBUVIR FOR GENOTYPE 2/3 HEPATITIS C INFECTED PATIENTS

29/11/2012

Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting)

22/11/2012

Treatment of Hepatitis C Genotype 1 Patients with Severe Fibrosis or Compensated Cirrhosis: The International Telaprevir Early Access Program

22/11/2012

FDA approves new indication for PROMACTAÂ® (eltrombopag)

22/11/2012

Safety and Sustained Viral Response of MK-5172 for 12 Weeks in Combination With Pegylated Interferon Alfa-2b and Ribavirin for 24 Weeks in HCV Genotype 1 Treatment-Naive Noncirrhotic Patients

16/11/2012

Peginterferon Lambda‐1a (Lambda) Compared With Peginterferon Alfa‐2a (Alfa) in Treatment‐Naive Patients With HCV Genotypes 1 or 4: SVR24 Results From EMERGE Phase 2b

16/11/2012

First Report of Peginterferon Lambda/Ribavirin in Combination With Either Daclatasvir or Asunaprevir in HCV Genotype 1 Japanese Patients: Early Sustained Virologic Response (SVR4) Results From the D‐LITE Japanese Substudy

16/11/2012

Alisporivir (ALV) plus Peg-interferon/Ribavirin (P/R) Achieves High On-Treatment Undetectable HCV RNA Levels Among the Most Difficult to Treat HCV G1 Patients. Results of a Planned Treatment Week 24 Interim Analysis of a Randomized, Double Blind, Placebo

16/11/2012

Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: Final results from VITAL-1 study

16/11/2012

Sustained Virologic Response in Chronic HCV Genotype (GT) 1‐Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor) With or Without Peginterferon Alfa‐2a/Ribavirin (PEG/RBV)

13/11/2012

Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study

13/11/2012

Safety and tolerability of simeprevir (TMC435) in combination with peginterferon a-2a and ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and –experienced patients (Phase IIb PILLAR and ASPIRE Trials)

13/11/2012

OPTIMIZE Trial: Noninferiority of Twice-daily Telaprevir Versus Administration Every 8 Hours inTreatment-naïve, Genotype 1 HCV-infected Patients

13/11/2012

Efficacy and tolerability of simeprevir (TMC435) 150 mg once daily with peginterferon and ribavirin for treatment of HCV genotype 1 infection in patients with Metavir score F3 and F4 (PILLAR and ASPIRE trials)

13/11/2012

EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF FALDAPREVIR (BI 201335) + BI 207127 ± RIBAVIRIN IN TREATMENT-NAÏVE PATIENTS WITH HCV GT-1 AND COMPENSATED LIVER CIRRHOSIS: RESULTS FROM THE SOUND-C2 STUDY

12/11/2012

Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase II study including patients with advanced liver disease

12/11/2012

Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C

12/11/2012

Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily

12/11/2012

Pagina: 1 2 3 4 5

© Copyright 2015 - Associazione EpaC Onlus - C.F. 97375600158

Via Col. Tommaso Masala, 42
C/O Parco Altamira - 00148 Roma

Tel. 06.60200566 | Fax 06.60209056
Orari ufficio: 9.00-12.00 e 14.00-17.00

Via Luigi Cadorna, 17/A
20871 Vimercate Monza e Brianza

Tel. 0396083527 | Fax 039 6611523
Orari ufficio: 9.00-12.00 e 14.00-17.00

ACE - Alleanza Contro Epatiti World Hepatitis Alliance ELPA - European Liver Patients Associations